Stifel Reiterates Buy Rating on Renalytix AI Plc. (RNLX) After Medicare Delay
Tweet Send to a Friend
Stifel analyst Daniel Arias reiterated a Buy rating and $30.00 price target on Renalytix AI Plc. (NASDAQ: RNLX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
